Myasthenia Gravis - Pipeline Insight, 2024

This “Myasthenia Gravis - Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Myasthenia Gravis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Myasthenia Gravis Understanding

Myasthenia Gravis: Overview

Myasthenia gravis (MG) is the most common disorder affecting the neuromuscular junction (NMJ) of the skeletal muscles. The classic presentation is a fluctuating weakness that is more prominent in the afternoon. It usually involves muscles of the eyes, throat, and extremities. The reduced transmission of electrical impulses across the neuromuscular junction due to the formation of autoantibodies against the specific postsynaptic membrane proteins consequently causes muscle weakness. A wide variety of conditions can precipitate MG, such as infections, immunization, surgeries, and drugs. Myasthenia gravis causes a significant number of complications. These include myasthenic crisis, an acute respiratory paralysis that requires intensive care, as well as adverse events due to long term medication treatment like opportunistic infections and lymphoproliferative malignancies. A complete understanding of the pathophysiologic mechanisms, clinical manifestations, treatment strategies, and complications of myasthenia gravis is necessary for better patient care and outcomes.

Myasthenia Gravis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myasthenia Gravis pipeline landscape is provided which includes the disease overview and Myasthenia Gravis treatment guidelines. The assessment part of the report embraces, in depth Myasthenia Gravis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myasthenia Gravis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Myasthenia Gravis R&D. The therapies under development are focused on novel approaches to treat/improve Myasthenia Gravis.

Myasthenia Gravis Emerging Drugs Chapters

This segment of the Myasthenia Gravis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Myasthenia Gravis Emerging Drugs

Efgartigimod: ArgenxEfgartigimod is an investigational antibody fragment designed to decrease disease-causing immunoglobulin G (IgG) antibodies and inhibit the IgG recycling process. Results from Phase III clinical trial (ADAPT) showed treatment with efgartigimod provided clinically meaningful improvements in strength and quality of life measures in generalized myasthenia gravis (gMG). Efgartigimod is under U.S. Food and Drug Administration (FDA) review with December 17, 2021 Prescription Drug User Fee Act (PDUFA) target action date
Ravulizumab: Alexion PharmaceuticalsRavulizumab is the first and only long-acting C5 complement inhibitor. The medication works by inhibiting the C5 protein in the terminal complement cascade, a part of the body’s immune system. When activated in an uncontrolled manner, the complement cascade over-responds, leading the body to attack its own healthy cells. Alexion Pharmaceuticals reported positive topline results from a Phase III study evaluating the safety and efficacy of ravulizumab in adults with generalized myasthenia gravis (gMG). The company plans to make regulatory filings in the US, EU & Japan in late 2021 or early 2022, based on P-III results.

Inebilizumab: Horizon TherapeuticsInebilizumab is a monoclonal antibody that binds to a protein called CD-19, found on the surface of immune B-cells. The therapy was designed to deplete these cells, which play a central role in the progression of autoimmune diseases like MG. In a $3.05 billion deal, Horizon Therapeutics acquired Viela Bio, the developer of inebilizumab, a potential treatment for autoimmune diseases such as myasthenia gravis. The therapy is currently being investigated in people with MG in a Phase III clinical trial that is now recruiting participants in Columbia.

Myasthenia Gravis: Therapeutic Assessment

This segment of the report provides insights about the different Myasthenia Gravis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Myasthenia Gravis

There are approx. 20+ key companies which are developing the therapies for Myasthenia Gravis. The companies which have their Myasthenia Gravis drug candidates in the most advanced stage, i.e. Phase III include, Argenx.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Myasthenia Gravis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Myasthenia Gravis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myasthenia Gravis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myasthenia Gravis drugs.

Myasthenia Gravis Report Insights

• Myasthenia Gravis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Myasthenia Gravis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Myasthenia Gravis drugs?
• How many Myasthenia Gravis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myasthenia Gravis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Myasthenia Gravis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Myasthenia Gravis and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 1-3 business days.